Last updated: February 17, 2026
What is the current market status and price projection for NDC 00187-1496?
Product overview
NDC 00187-1496 refers to the drug Aflibercept Injection, marketed under the brand Eylea. It is an anti-VEGF agent approved for multiple retinal diseases, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Market size and demand
The global market for anti-VEGF therapies, including aflibercept, exceeds $14 billion annually. Eylea's leading position stems from its established patent portfolio and broad indications. The market is segmented into ophthalmology clinics, hospitals, and specialty pharmacies.
Key market drivers:
- Increasing prevalence of AMD, DME, and RVO.
- Growing awareness and diagnosis.
- Off-label use in other ocular conditions.
Competitive landscape:
- Ranibizumab (Lucentis): Market share roughly 50%.
- Bevacizumab (Avastin): Off-label use, significant price competition.
- Aflibercept (Eylea): Approx. 40% market share.
- Brolucizumab (Beovu): Emerging competitor.
Current sales figures
- Estimated global sales for Eylea in 2022: approximately $4.2 billion.
- North American market accounts for 60% of revenue.
- Pricing per dose varies:
| Region |
Price per Injection |
Notes |
| U.S. |
$1,950 |
Wholesale acquisition cost (WAC) |
| Europe |
€1,800 |
Approximate, varies by country |
| Asia |
$1,200-$1,500 |
Price sensitivity |
Price trends and projections
Historical trends:
- Pre-2020: Steady increase in prices due to patent protections and limited biosimilar competition.
- Post-2020: Price erosion begins as biosimilars and generics approach market entry.
Projection to 2027:
- U.S. pricing expected to decline by approximately 20-25% as biosimilars and cost containment policies expand.
- Europe and Asia likely to see a 15-20% reduction, influenced by healthcare system negotiations.
- Overall, the global market value may decline slightly to around $3.8 billion by 2027, assuming continued patent protections and moderate biosimilar adoption.
Impact of biosimilars and generics
- Biosimilar competition is intensifying. The first biosimilar to aflibercept received regulatory approval in Europe in 2022.
- Pricing for biosimilars typically comes 30-50% lower than originator prices.
- In the U.S., patent expiry expected around 2024-2025, leading to potential price reductions.
Policy and regulatory influences
- The U.S. FDA is prioritizing biosimilar approval to reduce drug costs.
- European Medicines Agency (EMA) has approved multiple biosimilars for aflibercept.
- Price negotiations in countries like Canada, Japan, and Australia are leading to price caps that impact overall revenue.
How are prices expected to evolve globally?
| Region |
Expected Price Change (2023-2027) |
Key Factors |
| U.S. |
-25% |
Biosimilar entries, policy shift |
| Europe |
-20% |
Healthcare negotiations, biosimilar uptake |
| Asia |
-15% to -20% |
Price sensitivity, market expansion |
Summary
Eylea (aflibercept) dominates the anti-VEGF market with substantial sales volume, but pricing will decline over the next five years due to biosimilar competition and healthcare policy reforms. Revenue projections suggest a slight decrease, with a shift toward more cost-effective therapies.
Key Takeaways
- Eylea's market share remains significant, supported by broad indications and clinician familiarity.
- Biosimilar competition is disrupting pricing, especially in the U.S. and Europe.
- Prices are projected to decline by approximately 20-25% globally over five years.
- Patent expiries around 2024-2025 will accelerate price erosion.
- Market growth will slow but remain stable due to increasing demand in ophthalmology.
FAQs
1. When will biosimilars for aflibercept enter the U.S. market?
Patent expiry is expected around 2024-2025, with biosimilar filings already underway.
2. How will biosimilars affect Eylea's pricing?
Biosimilars are expected to reduce prices by 30-50%, leading to decreased revenue for the originator drug.
3. What indications are driving Eylea's sales growth?
Wet AMD (approximately 60%), DME, and RVO are primary drivers.
4. Are there regulatory barriers to biosimilar approval?
Yes. Biosimilars must demonstrate similar safety, efficacy, and quality, but regulatory pathways are streamlined in many regions.
5. How do regional policies influence drug prices?
Price caps, negotiation processes, and reimbursement policies vary, impacting final consumer prices.
References
[1] IQVIA, "Global Ophthalmic Market Report,” 2022.
[2] European Medicines Agency, "Biosimilar Approvals," 2022.
[3] U.S. Food and Drug Administration, "Biosimilar Development & Approval," 2023.
[4] EvaluatePharma, "Anti-VEGF Market Outlook," 2022.
